Celera Corporation releases review content on KIF6 gene variant for CHD Celera Corporation today announced the publication of an assessment article on the KIF6 gene variant as a predictor of threat of coronary heart disease and reduction of CHD occasions from statin therapy. These included the total results of genetic research of 4 landmark prospective, randomized scientific trials, the gold regular for clinical research, in which it was found that statin therapy decreased CHD events in KIF6 719Arg carriers significantly, but not in noncarriers.In the Grouse Room. This event is co-hosted by CAN and The Arthritis Society and media should attend. CAN want to gratefully acknowledge the next sponsors for his or her support: Abbott, Roche and sanofi aventis. Attention broadcast mass media: a Canadian Arthritis Network Dvd and blu-ray which has b-roll and testimonials can be available for broadcast use. Make sure you inquire if interested.
Caregivers of stroke survivors are at risk for complications and major depression from chronic stress Caregivers of stroke survivors are at risk for developing problems and unhappiness from chronic stress, according to a report published by researchers in the Loyola University Chicago Marcella Niehoff School of Nursing in the most recent problem of Biological Analysis for Nursing.